18 results about "Probenecid" patented technology

The invention relates to a method for removing halogenated alkyl toxic impurities in probenecid sodium, which is characterized by comprising the following steps of: 1, heating and hydrolyzing excessive halogenated alkyl under an alkaline condition to remove the halogenated alkyl toxic impurities; 2, organic solvent extraction and removal; 3, adsorption removal by a specific adsorption column; after the treatment by the method, the residue of haloalkane is reduced to be not detected from 15-100ppm, and the limit requirements of related genotoxic impurities in Chinese drug registration regulations and ICH guidance principles are completely met.

Disclosed herein are methods, compounds, and compositions for treating or preventing an inflammasome-mediated disease or condition, including an inflammasome-mediated pulmonary disease or condition.

The invention relates to a method for determining the content of di-n-propylamine impurities in probenecid sodium. The method is characterized by comprising the following steps: 1) preparing a blank solution; 2) preparing a reference solution; 3) preparing a test solution; 4) giving chromatographic conditions; 5) system applicability requirement; 6) precisely measuring the test solution and the reference solution by a determination method, respectively injecting into a gas chromatograph, recording chromatograms, and calculating the content according to an external standard method; the content of the di-n-propylamine impurity in the probenecid sodium can be effectively and accurately detected. The established gas chromatographic method for determining the probenecid sodium di-n-propylamine impurity has the advantages of strong specificity, high sensitivity, good linearity and good accuracy, and can provide research reference for quality control and evaluation of the probenecid sodium di-n-propylamine impurity.

The invention relates to a process for purifying and salifying a probenecid crude product, which is characterized in that the purpose of removing organic impurities, inorganic impurities and harmful solvent residues in the probenecid crude product is achieved by utilizing the dissolvability difference of probenecid acid and salt thereof and transferring the probenecid acid and the salt thereof in a water phase and an organic phase for many times, and a high-purity probenecid solution is obtained. And reacting the probenecid solution with a salt-forming agent to obtain the probenecid sodium. The purity of the probenecid purified by the process can reach more than 99.9% (HPLC), solid-liquid separation and intermediate drying are not needed in the purification and salification processes, continuous production can be realized, the production period is shortened, and the process is suitable for industrial production.

The invention discloses a eutectic probenecid soluble microneedle as well as a preparation method and application thereof, and belongs to the technical field of microneedle preparations. The technical problem to be solved is to provide the preparation method of the deep-eutectic probenecid soluble microneedle with excellent mechanical property and better dissolution and transdermal penetration capacity. The deep-eutectic probenecid soluble microneedle disclosed by the invention improves the solubility and bioavailability of probenecid. The key point of the technical scheme is as follows: the eutectic probenecid soluble microneedle comprises the following components: probenecid, a eutectic solvent and a matrix material, wherein the eutectic solvent comprises basic amino acid and polyhydric alcohol; the molar ratio of the basic amino acid to the polyhydric alcohol is 1: (5-7.5).

The present disclosure relates to a combination of valproic acid or a pharmaceutically acceptable salt thereof, a β-lactam compound or a pharmaceutically acceptable salt thereof, and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing disease using this combination.

Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated diseases or conditions, including inflammasome-mediated lung diseases or conditions.

Compositions and methods of treating a coronavirus infection in a subject are provided. The methods generally include administering to the subject an effective amount of a probenecid, metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can be therapeutic and / or prophylactic. The amount of probenecid, metabolite or analog thereof, or a pharmaceutically acceptable salt thereof can be effective, for example, to reduce viral replication, reduce one or more symptoms of a disease, disorder, or illness associated with the virus, or a combination thereof. In preferred embodiments, the virus is a severe acute respiratory syndrome-associated coronavirus, such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-associated coronavirus, such as MERS-CoV, or a coronavirus that causes the common cold.

The present disclosure relates to bilayer tablets comprising a second layer comprising a β-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated dermatological diseases or conditions.

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.

The present invention discloses a compound comprising quercetin and probenecid derived from the Japanese blueberry tree, as well as its preparation method and application. The compound comprising quercetin and probenecid derived from the Japanese blueberry tree of the present invention has a structural formula as shown in Formula (I): #imgabs0# The compound comprising quercetin and probenecid derived from the Japanese blueberry tree of the present invention is synthesized through a series of chemical reaction steps, including solvent dissolution, heating and stirring, vacuum concentration, extraction, and silica gel column chromatography. The derivative of the quercetin and probenecid derived from the Japanese blueberry tree of the present invention exhibits enhanced biological activity and therapeutic effects through structural modification. The compound of the present invention has a significant effect on lowering blood uric acid, blood sugar, and serum total cholesterol, and increasing serum total protein levels in experimental mice.

The present invention relates to probenecid or a pharmaceutically acceptable salt thereof for use in the treatment of neurological disorders in a subject in need thereof wherein administration of probenecid or a pharmaceutically acceptable salt thereof controls clinical or electrographic seizures in said subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.

The invention relates to a preparation method for salifying and freeze-drying probenecid, which is characterized by comprising the following steps: reacting probenecid and a salt-forming agent in injection water to form salt, adding a pH regulator to regulate the pH value, adding absolute ethyl alcohol, adsorbing and decolorizing with activated carbon, filtering, and freeze-drying to obtain the product, the probenecid comprises probenecid, sodium hydroxide and sodium carbonate according to a molar ratio of 1: 1: 0.01, a solvent is injection water containing 3%-5% of ethanol, and freeze-drying comprises pre-freezing, annealing, heating to melt small ice crystals, and re-freezing. The probenecid sodium freeze-dried powder is good in appearance property, stable in salt forming rate, controllable in pH and capable of improving the redissolution time, the product freeze-drying process efficiency is improved, and it is guaranteed that the product quality is controllable. The process is simple and suitable for industrial production.

The present disclosure relates to a combination of valproic acid or a pharmaceutically acceptable salt thereof, a β-lactam compound or a pharmaceutically acceptable salt thereof, and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a method of using the combination for treating or preventing a disease.

The invention discloses a human trophoblast organ-like model and a construction method and application thereof. The method comprises the following steps: firstly, digesting and separating trophoblast cells from human placenta villus, inoculating the trophoblast cells into matrigel, and adding an ADMEM / F12 culture medium containing specific growth factors for culturing to form trophoblast-like organs; then morphological observation is carried out, and expression of P-gp, BCRP and MRP1 / 2 is detected from mRNA and protein level to carry out model verification; a co-incubation method is adopted, a plurality of ABC transporter specific substrates are adopted, and the influence of verapamil, KO143 and probenecid on the transportation of the ABC transporter specific substrates is researched; and finally, the method is applied to evaluation of substrate transport inhibition of a clinical drug on the ABC transporter protein. The human trophoblast organ model is constructed for the first time and is applied to ABC transporter mediated drug transport research, the operation method is efficient and rapid, and the organ model can be widely applied to in-vitro high-throughput screening of clinical drugs on ABC transporter inhibitors. The method has a wide application prospect.

Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.